RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
' RIPK1 Inhibitor Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market.
The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the RIPK1 Inhibitor Pipeline Report:
Companies across the globe are diligently working toward developing novel RIPK1 Inhibitor treatment therapies with a considerable amount of success over the years. RIPK1 Inhibitor Key players such as - Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others, are developing therapies for the RIPK1 Inhibitor treatment
RIPK1 Inhibitor Emerging therapies such as - SAR443122, GFH312, R552, and others are expected to have a significant impact on the RIPK1 Inhibitor market in the coming years.
In May 2025, Accropeutics' investigational drug has successfully met the primary objectives in a Phase 2 clinical trial for psoriasis conducted in China, leading the company to commit to accelerating the clinical advancement of its TYK2/JAK1 inhibitor, AC-201. In the trial, 145 Chinese patients with moderate to severe plaque psoriasis were administered one of three doses of AC-201 or a placebo. All dosing groups achieved the primary endpoint, with a significantly higher proportion of patients reaching a 75% improvement in their Psoriasis Area and Severity Score (PASI 75) at Week 12 compared to the placebo group.
In October 2024, Sanofi discontinued its Phase 2 clinical trial of oditrasertib, an experimental RIPK1 inhibitor, in patients with relapsing and progressive multiple sclerosis (MS) after the treatment did not achieve its primary objectives. Initiated early last year, the trial failed to demonstrate a significant reduction in neurofilament light chain (NfL) levels — a biomarker associated with neurodegeneration. Additionally, the therapy did not meet any major secondary endpoints, as noted in a recent SEC filing by Denali Therapeutics, Sanofi's development partner.
RIPK1 Inhibitor Overview
A RIPK1 inhibitor is a type of drug that blocks the activity of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) — an enzyme involved in regulating inflammation, cell death (especially necroptosis), and immune responses. Overactivation of RIPK1 has been linked to several diseases, including autoimmune disorders, neurodegenerative conditions, and inflammatory diseases. By inhibiting RIPK1, these drugs aim to reduce excessive inflammation and tissue damage, offering a promising therapeutic strategy for conditions like multiple sclerosis, Alzheimer's disease, and psoriasis.
Emerging RIPK1 Inhibitor Drugs Under Different Phases of Clinical Development Include:
RIPK1 Inhibitor Pipeline Therapeutics Assessment
RIPK1 Inhibitor Assessment by Product Type
RIPK1 Inhibitor By Stage and Product Type
RIPK1 Inhibitor Assessment by Route of Administration
RIPK1 Inhibitor By Stage and Route of Administration
RIPK1 Inhibitor Assessment by Molecule Type
RIPK1 Inhibitor by Stage and Molecule Type
DelveInsight's RIPK1 Inhibitor Report covers around 12+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Download Sample PDF Report to know more about RIPK1 Inhibitor drugs and therapies
RIPK1 Inhibitor Pipeline Analysis:
The RIPK1 Inhibitor pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the RIPK1 Inhibitor treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment.
RIPK1 Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of RIPK1 Inhibitor Pipeline Drug Insight
Table of Contents
1
RIPK1 Inhibitor Report Introduction
2
RIPK1 Inhibitor Executive Summary
3
RIPK1 Inhibitor Overview
4
RIPK1 Inhibitor- Analytical Perspective In-depth Commercial Assessment
5
RIPK1 Inhibitor Pipeline Therapeutics
6
RIPK1 Inhibitor Late Stage Products (Phase II/III)
7
RIPK1 Inhibitor Mid Stage Products (Phase II)
8
RIPK1 Inhibitor Early Stage Products (Phase I)
9
RIPK1 Inhibitor Preclinical Stage Products
10
RIPK1 Inhibitor Therapeutics Assessment
11
RIPK1 Inhibitor Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
RIPK1 Inhibitor Key Companies
14
RIPK1 Inhibitor Key Products
15
RIPK1 Inhibitor Unmet Needs
16
RIPK1 Inhibitor Market Drivers and Barriers
17
RIPK1 Inhibitor Future Perspectives and Conclusion
18
RIPK1 Inhibitor Analyst Views
19
Appendix
20
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Navitas Semiconductor Focuses on AI and Energy Growth
Navitas Semiconductor Corporation ( (NVTS)) has released its Q2 earnings. Here is a breakdown of the information Navitas Semiconductor Corporation presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Navitas Semiconductor Corporation, a leader in gallium nitride (GaN) power ICs and silicon carbide (SiC) technology, focuses on next-generation power semiconductors for AI data centers and energy infrastructure. The company reported a revenue of $14.5 million for the second quarter of 2025, with a strategic pivot towards AI data centers and energy infrastructure, supported by a $100 million capital raise and a new manufacturing partnership. Key financial highlights include a reduction in GAAP loss from operations to $21.7 million and an increase in cash reserves to $161.2 million. Navitas has partnered with NVIDIA to develop next-generation 800V data centers, leveraging its GaN and SiC technologies across three power conversion stages, with a significant market potential projected by 2030. Looking ahead, Navitas plans to focus on high-end mobile, consumer, and appliance segments while expanding its presence in AI data centers and energy infrastructure, anticipating a challenging but promising growth trajectory.
Globe and Mail
3 hours ago
- Globe and Mail
Contineum (CTNM) Q2 R&D Jumps 78%
Key Points GAAP net loss per share widened to $(0.62) in Q2 2025, missing analyst GAAP EPS estimates by $0.18, driven by a sharp rise in research and development expenses. R&D expenses surged 78%, reflecting increased investment in clinical pipeline programs, while cash reserves stood at $175.5 million. These 10 stocks could mint the next wave of millionaires › Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotechnology company focused on developing treatments for serious diseases such as pulmonary fibrosis, multiple sclerosis, and depression, released its second quarter fiscal 2025 results on August 5, 2025. The most notable news in the earnings release was a wider GAAP net loss per share of $(0.62), missing the estimate of $(0.44). Research and development expenses (GAAP) saw a sharp rise as the company continued to advance its clinical pipeline. Management reported a robust cash position of $175.5 million as of June 30, 2025. Overall, the period reflected ongoing progress in pipeline development, but came with significantly higher spending and a continued absence of commercial revenue. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) ($0.62) ($0.44) ($0.39) (-59.0%) Revenue N/A $7.5 million N/A — Research and Development Expense $14.1 million $7.9 million 78.5% General and Administrative Expense $3.8 million $3.0 million 26.7% Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Key Success Factors Contineum Therapeutics develops small molecule therapies for diseases with high unmet medical need. Its clinical programs focus on two main drug candidates: PIPE-791, an oral treatment being studied for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain; and PIPE-307, a selective M1R antagonist for use in depression and relapsing-remitting multiple sclerosis (RRMS). The company's pipeline also includes earlier-stage assets like CTX-343, a peripherally restricted LPA1R antagonist. Contineum has centered its business on advancing clinical trials for PIPE-791 and PIPE-307. Key success factors for the company include achieving positive clinical trial results, securing regulatory approvals, maintaining strategic partnerships (particularly with Johnson & Johnson for PIPE-307), and ensuring sufficient cash to fund ongoing development. A core part of its strategy relies on addressing conditions such as IPF and RRMS, where few effective therapies are available. Quarter Highlights and Financial Developments Contineum significantly increased its investment in research and development. This sharp rise was tied to the progression of clinical trials for both PIPE-791 and PIPE-307 and expanded workforce costs to support these activities. General and administrative expenses also increased, primarily due to higher stock-based compensation and salaries. GAAP net loss increased compared to the prior-year quarter. The absence of significant top-line revenue is typical for pre-commercial biotechnology companies at this stage. Management highlighted that all ongoing spending aligns with planned development milestones, focusing resources on advancing the pipeline rather than generating current sales. Operationally, the most notable achievements included advancing PIPE-791 in multiple indications. PIPE-791 is an oral drug designed to block LPA1R, a receptor implicated in the progression of fibrotic and neurodegenerative disorders. Management completed chronic toxicity studies for PIPE-791 and advanced plans for regulatory filings to begin a global Phase 2 trial for IPF later in 2025. Patient dosing started in a Phase 1b trial for chronic pain in March 2025, with results expected in the first half of 2026. The company postponed the planned Phase 2 study in progressive multiple sclerosis, choosing to concentrate resources on IPF instead. PIPE-307, intended for both RRMS and major depressive disorder (MDD), is in the VISTA Phase 2 proof-of-concept trial in RRMS. Top-line data are expected in the fourth quarter of 2025. Separately, Johnson & Johnson, through its Janssen business, launched recruitment in December 2024 for a Phase 2 trial testing PIPE-307 in adults with MDD. No new partnership deals or milestone payments were reported during the quarter. Strategic Focus, Program Prioritization, and Cash Updates Contineum made several program prioritization decisions during the period. It postponed starting clinical trials for PIPE-791 in PrMS and the first-in-human studies for CTX-343, focusing its resources on the largest near-term market opportunity in IPF. The company ended the quarter with $175.5 million in cash, cash equivalents, and marketable securities. This cash position should enable Contineum to fund operations through 2027, according to management. In July 2025, the company generated approximately $8.4 million in additional cash through an at-the-market stock offering, issuing 2,122,000 shares. The cash level reduces short-term financing risk, but ongoing operating losses and persistent R&D investment mean further funding might be required if programs take longer or cost more than anticipated. Management reaffirmed its focus on advancing the most promising pipeline programs and signaled no change in strategic partnerships or cash material events aside from the ATM offering. The pipeline's pace and development depend heavily on positive results from ongoing and upcoming clinical trials, particularly for PIPE-791 in IPF and PIPE-307 in RRMS and MDD. The company did not announce or adjust any dividend. Outlook and Guidance Contineum did not provide explicit guidance or financial forecasts for the next quarter or the remainder of fiscal 2025. Management referenced its strong cash position as sufficient to support planned development activities through 2027 but did not give revenue, expense, or earnings targets. Looking ahead, investors will likely track the timing and outcomes of the planned clinical milestones for PIPE-791 and PIPE-307, enrollment trends, and any updates on delayed programs or additional partnership deals. Risks remain tied to clinical trial outcomes, future cash burn trends, and the company's ability to access additional non-dilutive funding if needed. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
9 hours ago
- Globe and Mail
Watts Water Technologies, Inc. Declares Quarterly Dividend
Watts Water Technologies, Inc. (NYSE: WTS) today declared that the Corporation will pay a quarterly dividend of fifty-two cents ($0.52) per share on each outstanding share of the Company's Class A Common Stock and Class B Common Stock, said dividend to be paid on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world. Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions to control the efficiency, safety, and quality of water within commercial, residential, and industrial applications. For more information visit
